Positive news at the beginning of 2012 for Athersys, who yesterday announced that it had been successfully granted US patent to cover the use of non-embryonic multipotent stem cells for the treatment of cardiovascular conditions including myocardial infarction, congestive heart failure, myocardial ischemia and other heart conditions. Full article here.
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.
Gil van Bokkelen, Chairman and CEO, Athersys will be an integral speaker at the 7th Annual World Stem Cells & Regenerative Medicine Congress in London. This executive level congress is bringing together leading pharma, biotech, academia, regulators and payers to strategise the future opportunities and challenges in commercialising stem cell based therapies.